Following the sad passing of Prof Alan Clarke last year, we have appointed a new lead to continue Alan's legacy.
Dr Richard Clarkson has taken up the mantle and we are sure he will bring great results to our signalling and stem cell research.
He brings with him a wealth of experience. He is Senior Lecturer in cancer research at the European Cancer Stem Cell Research Institute, University of Cardiff School of Biosciences. He is also co-founder of Tiziana Life Sciences Plc, an AIM-listed biotech company which has entered into exclusive licenses for two first-in-class anti-cancer agents, including a novel anti-cancer stem cell agent.
Richard received his PhD from the Faculty of Medicine, University of Manchester and carried out research at the Universities of Queensland, Edinburgh and Cambridge before moving to Cardiff in 2005. Having worked for more than 10 years on the biology of the mammary gland and the regulation of epithelial cell apoptosis, Richard’s research group now focuses on applying this knowledge to identify novel therapeutic strategies to eliminate or modify the cancer cells responsible for the spread of tumours around the body, the main cause of deaths in cancer patients.
We look forward to seeing the benefits of having Richard on board, and will keep you updated here.